November Election in the US: Psychedelics 

Psychedelics and Biotech    

Psychedelics investments have gained considerable  interest due to their potential therapeutic applications. Leading biotech companies and research institutions are studying psychedelics for their potential in treating prevalent mental health conditions like depression, PTSD, and anxiety disorders. These treatments have shown promise in clinical trials, which has encouraged biotech firms to invest in further research and drug development.

Biotech Companies are focusing on optimizing the delivery of psychedelic compounds through proprietary formulations and therapeutic protocols to improve efficacy and safety. This trend is being driven by a growing body of scientific evidence that psychedelics can induce neuroplasticity—restructuring brain connections that may offer long-lasting relief from various mental health issues.

States Voting on Psychedelic Laws

This November, Massachusetts voters will decide on the legalization of psychedelics through Question 4. If passed, the measure would permit individuals aged 21 and older to grow, possess, and use personal amounts of natural psychedelic substances. Additionally, it would establish a psychedelic substance commission and advisory board to oversee regulation and licensing.

With adult-use cannabis already legal in Massachusetts, approval of this measure would make the state the third in the country, after Oregon and Colorado, to legalize natural psychedelics. Currently, 10 states have reform efforts in regard to psychedelic compounds and 5 states have select cities where certain psychedelics are decriminalized.

Politics and Psychedelics

While neither Republican or Democratic presidential candidates have publicly addressed psychedelic policies, an interesting moment occurred when podcaster Lex Fridman, in an interview with Trump, quipped, “We would probably have a better world if everybody in Congress took some mushrooms,” to which Trump laughed and shifted the conversation back to cannabis.

About 45% of adults in the U.S. support the legalization of certain psychedelics for treating mental health conditions under professional supervision. Interest in psychedelics is growing, though at a slower pace than cannabis, as research continues to highlight their therapeutic potential. For investors, this could mean a broader range of investment options, enhanced liquidity, and stronger valuations for psychedelic-related investments. Specialized ETFs focusing on psychedelics are an option to provide investors with diversified exposure to the sector. These funds are designed to capitalize on the long-term potential of the psychedelic space as it matures, driven by ongoing clinical success and expanding legal access, while potentially mitigating risk.

The opinions expressed in this publication are those of the authors and are subject to change. They do not purport to reflect the opinions or views of ETF Central or its members. ETF central does not guarantee the accuracy, completeness, or reliability of the information provided.

Sources: 

1. https://www.newsweek.com/drug-use-ballot-november-states-map-1967694
2. https://today.yougov.com/society/articles/43267-one-in-four-americans-have-tried-psychedelic-drugs
3. https://thehill.com/changing-america/well-being/mental-health/3703454-nearly-half-of-u-s-adults-support-legalizing-some-psychedelics-for-mental-health-treatment/
4. https://law.vanderbilt.edu/will-the-movement-to-legalize-psychedelics-succeed/
5. https://www.hindustantimes.com/world-news/us-news/trump-laughs-off-psychedelic-congress-idea-as-he-pushes-controlled-marijuana-laws-101725437946930.html
6. https://www.biospace.com/drug-development/massachusetts-proposal-to-legalize-plant-based-psychedelics-ahead-of-science-experts